Transcode Therapeutics, Inc.
TransCode Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing RNA-targeted cancer therapies. Its lead program, TTX-MC138, is designed for metastatic tumors that overexpress microRNA-10b, with research and development centered on advanced malignancies.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDevelopment of TTX-MC138 and related oncology drug candidates targeting metastatic cancer biology.
Discovery and laboratory research supporting target validation, biomarker work, and candidate selection.
Clinical trial planning, execution, and regulatory preparation for cancer therapeutics.
Customers
TransCode does not currently sell approved products, so its direct customers are not traditional commercial buyers. Its economic counterparties are research partners, clinical trial vendors, contract manufacturers, and potential future licensing or development partners that support or fund drug development. If its programs succeed, the eventual end customers would be hospitals, oncologists, and patients treated with approved cancer therapies.
CROs, labs, and manufacturers that provide preclinical, analytical, and clinical trial services.
Universities and research institutions that collaborate on sponsored studies and translational work.
Pharma or biotech partners that may license or co-develop oncology assets.
Patients with advanced malignancies who could use approved therapies if development succeeds.
Strategy
The company’s strategy is to advance its lead oncology candidate through preclinical and clinical development while relying on external partners for much of the scientific and manufacturing work. It is also focused on preserving capital, using sponsored research and third-party service providers to support development until a clearer path to regulatory approval or partnering emerges.
Clinical and regulatory progress is the main value-creation path for a pre-revenue biotech.
The company depends on third parties for studies, analytics, and drug product work.
A small operating base helps extend runway while development remains uncertain.
Geography
TransCode is headquartered in the United States and conducts its business activities primarily from Massachusetts, with research collaboration tied to Michigan State University. Its operating footprint is domestic and research-oriented, but its therapeutic programs and regulatory pathway are tied to U.S. FDA oversight and the broader U.S. biotechnology ecosystem.
Risks
TransCode faces the typical risks of a pre-revenue biotechnology company: clinical failure, regulatory delay, and dependence on external funding and partners. Its reported risks also highlight Nasdaq listing risk, FDA policy uncertainty, and the possibility that additional financing may not be available on acceptable terms, which could force further reductions in development activity.
- Failure to develop or commercialize a marketable productImpact: CriticalLikelihood: High
The company is still in development and has no approved therapy to sell.
Exposure: TTX-MC138 and future oncology candidates
- Insufficient financingImpact: CriticalLikelihood: High
Drug development requires ongoing capital and the company may need to cut programs if funding is unavailable.
Exposure: R&D pipeline and operating continuity
- Nasdaq Capital Market delistingImpact: HighLikelihood: High
Loss of listing would likely reduce liquidity and make capital raising harder.
Exposure: Public market access and share value
- FDA and regulatory uncertaintyImpact: HighLikelihood: Medium
Approval timelines and guidance can shift with policy changes or agency disruptions.
Exposure: Clinical development and approval pathway
- Third-party dependencyImpact: Medium
The company relies on CROs, labs, and manufacturers for core development work.
Exposure
Accounting
Judgemental itemsManagement estimates work completed by vendors and clinical sites at each reporting date.
Impact: Can shift expenses between periods and affect operating loss timing
Equity awards are a meaningful cost for a small biotech workforce.
Impact: Affects general and administrative and total operating expense
Any future partner agreements would need careful contract and milestone accounting.
Impact: Could create uneven revenue recognition if deals are signed
Similar listed companies
Publicly listed companies with a comparable business focus.
Oncotelic Therapeutics, Inc.
OTLC · Pharmaceutical Preparations
Decoy Therapeutics Inc.
DCOY · Pharmaceutical Preparations
Intensity Therapeutics, Inc
INTS · Biological Products, (No Diagnostic Substances)
Terns Pharmaceuticals, Inc.
Pharmaceutical Preparations
Tectonic Therapeutic, Inc.
TECX · Biological Products, (No Diagnostic Substances)
Context Therapeutics Inc.
CNTX · Pharmaceutical Preparations
Last updated: 24/09/2026